Drug Trial Radar · NCT00981227
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
Last checked: Nov 20, 2026Latest source record: Oct 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
567
Actual
Start
Nov 2007
Primary completion
Jan 2009
Study completion Jan 2009
Sponsor
- Lead sponsor
- Bial - Portela C S.A.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with post-herpetic neuralgia.
Conditions
- Postherpetic Neuralgia
Interventions
Eslicarbazepine acetateDrug
Scored tablets
PlaceboDrug
oral route
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Mean Pain (NRPS) From Baseline to Endpoint in Mean PainTime frame: baseline and 13 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.